Latest News
Watchdog plans to tackle poor mobile phone coverage
Ofcom has published its proposed programme of work for the next financial year, including supporting the government as it quits the European Union and improving mobile phone coverage across the UK.
Nexstar to buy Tribune Media in $6.4bn deal
Nexstar Media Group has agreed to buy Tribune Media Company in a $6. 4bn deal.
Autolus reports early progress with cancer drugs
Autolus Therapeutics reported progress in clinical trials for one of its cancer treatments and said it has begun dosing patients in another trial.
GlaxoSmithKline to buy oncology-focused Tesaro for $5.1bn
GlaxoSmithKline has agreed to buy US-based oncology-focused pharmaceutical group Tesaro Inc for around $5. 1bn (£4bn).
ULS Technology expands market share despite property market challenges
ULS Technology reported on Monday that its interim profits grew after the company increased its market share in the re-mortgaging sector despite lower year-on-year housing market transactions.
Imaginatik wins 'significant' contract with new customer
Imaginatik said on Monday that it has won a "significant" contract with a new customer - a global chemical conglomerate - worth $142,000 a year.
Unilever agrees £3.1bn Horlicks deal with GSK
Unilever has struck a deal to buy Horlicks and other nutrition brands listed in India and Bangladesh from GlaxoSmithKline for roughly £3. 1bn.
Ted Baker to investigate 'forced hugs' culture; shares tumble
Ted Baker shares tumbled on Monday as it said it will launch an investigation following a petition from its staff over a culture of "forced hugs" at the company, with founder and chief executive officer Ray Kelvin under fire for his behaviour.
Urban Exposure closes more than £110m in new loans during November
Asset management firm Urban Exposure closed more than £110m in new loans in November, bringing its total lending commitments since its May IPO to £340m.
US pre-open: Stocks to rally on Sino-US trade truce
US stocks looked set to kick off the week with strong gains as investors welcome a 90-day trade truce between the US and China.
London midday: Stocks extend gains as trade truce boosts risk appetite
London stocks had extended gains by midday on Monday, with miners and energy issues leading the advance as news of a 90-day trade truce between the US and China boosted risk appetite.
Spirax sells HygroMatik unit to Italy's Carel for €59m
Spirax-Sarco Engineering said it had sold its German HygroMatik unit to Italian firm Carel Industries for €59m (£52. 3m).
AFH Financial ties up biggest ever acquisition
Financial planner AFH Financial has completed the largest purchase in its 27-year history, acquiring Yorkshire-based wealth management and investments outfit CTL Three for a total of £10m.
ECO Animal Health enters development deal with Agrinnovation
ECO Animal Health has entered a development and licensing deal with Agrinnovation and the Yissum Research Development Company of the Hebrew University of Jerusalem, it announced on Monday.
Egdon Resources sees production pick up at Ceres following flowmeter installation
Egdon Resources saw gas production hit 1. 16m cubic feet at its Ceres asset in the North Sea last month - the project's first full production month following the installation of a new flowmeter in October.
Factories report modest recovery in November, but outlook remains bleak
The manufacturing sector saw a slight rebound in activity in November, data showed on Monday, but optimism for the future sank to fresh lows as Brexit uncertainties weighed heavily.
Yourgene Health international expansion sees revenue jump 45%
Yourgene Health’s shares dropped on Monday as the company returned a loss even after interim revenue increased by almost 50%.
Mercia Technologies profits soar as revenues strengthen and expenses narrow
Mercia Technologies saw interim profits soar as a result of increased performance fees and narrowed expenses.
Plastics Capital sees decent first-half growth
Niche plastics products manufacturer Plastics Capital issued its unaudited interim results for the six months ended 30 September on Monday, which were reportedly in line with its own expectations.
Faron Pharmaceuticals applies to begin Clevegen clinical trials
Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that its clinical trial application to conduct a Phase I/II study with ‘Clevegen’, its wholly-owned novel precision cancer immunotherapy drug in development for the treatment of selected metastatic or inoperable tumours, has been approved by the Finnish Medicines Agency (FIMEA).